未找到相关数据
HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up
被引：16
作者：
Goldhirsch, A.
Piccart-Gebhart, M. J.
Procter, M.
de Azambuja, E.
Weber, H. A.
Untch, M.
Smith, I.
Gianni, L.
Jackisch, C.
Cameron, D.
Bell, R.
Dowsett, M.
Gelber, R. D.
Leyland-Jones, B.
Baselga, J.
机构：
[1] European Inst Oncol, Milan, Italy
[2] Univ Libre Bruxelles, BrEAST Data Ctr, Inst Jules Bordet, Brussels, Belgium
[3] Frontier Sci Scotland Ltd, Kincraig, Kingussie, Scotland
[4] F Hoffmann La Roche, Basel, Switzerland
[5] Charite, Helios Klinikum Berlin Buch, Akad LK, D-13353 Berlin, Germany
[6] Royal Marsden Hosp, London SW3 6JJ, England
[7] Inst Canc Res, London SW3 6JB, England
[8] Ist Sci San Raffaele, I-20132 Milan, Italy
[9] Klinikum Offenbach, Offenbach, Germany
[10] Univ Edinburgh, Western Gen Hosp, Edinburgh, Midlothian, Scotland
[11] Geelong Hosp, Geelong, Vic, Australia
[12] Royal Marsden NHS Trust, London, England
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Sanford Res, Sioux Falls, SD USA
[15] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
关键词：
D O I：
10.1158/0008-5472.SABCS12-S5-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
S5-2
引用
收藏
页数：1
相关论文